Références

1. de Wit M, Fijneman RJ, Verheul HM, Meijer GA, Jimenez Protéomique dans la recherche translationnelle sur le cancer colorectal: la découverte de biomarqueurs pour des applications cliniques46:..

2. Clin Biochem 2013, 466-479

3. Lin L, J Piao, Gao W, Y Piao, Jin G, Ma Y, Li J, Lin Z: DEK sur l'expression comme un biomarqueur indépendant de mauvais pronostic dans le cancer colorectalBioMed.

4. BMC Cancer 2013, 13:366

5. Abe M, Manola JB, Oh WK, Parslow DL, George DJ, Austin CL, Kantoff PW: Les concentrations plasmatiques de la protéine de choc thermique 70 chez les patients atteints de cancer de la prostate: un biomarqueur potentiel du cancer de la prostate3.

6. Cancer Clin prostate 2004, 49- 53.

7. Fujita Y, Nakanishi T, Miyamoto Y, Hiramatsu M, Mabuchi H, Miyamoto A, Shimizu A, Takubo T, Tanigawa N: identification basée sur la protéomique des auto-anticorps contre la protéine de choc thermique 70 comme marqueur diagnostique dans le carcinome spinocellulaire de l'œsophageLett.

8. Cancer 2008, 263:.280-290

<

9. Ciocca DR, Calderwood SK: .les protéines de choc thermique dans le cancer: diagnostic, de pronostic, de prévision, et les implications de traitement

10. stress cellulaire Chaperons 2005, 10:.86-103

11. Calini V, Urani C, Camatini M: La surexpression de HSP70 est induite par les rayonnements ionisants dans C3H 10 T1 / 2 cellules et protège contre les dommages de l'ADN17:..

12. in vitro Toxicol 2003, 561-566

13. Rerole AL, Jego G, Garrido C: Hsp70: protéine anti-apoptotique et tumorigène787:..

14. Methods Mol Biol 2011, 205-230

15. Multhoff G: protéine de choc thermique 70 (Hsp70): localisation membrane, l'exportation et la pertinenceimmunologiques43:..

16. des méthodes 2007, 229-237

17. Lancaster GI, Febbraio MA: Exosome-dependent trafficking of HSP70: a novel secretory pathway for cellular stress proteins.

18. J Biol Chem 2005, 280:23349-23355.

19. Asea A, Kraeft SK, Kurt-Jones EA, Stevenson MA, Chen LB, Finberg RW, Koo GC, Calderwood SK: HSP70 stimulates cytokine production through a CD14-dependant pathway, demonstrating its dual role as a chaperone and cytokine.

20. Nat Med 2000, 6:435-442.
    

21. Gross C, Hansch D, Gastpar R, Multhoff G: Interaction of heat shock protein 70 peptide with NK cells involves the NK receptor CD94.

22. Biol Chem 2003, 384:267-279.

23. Gastpar R, Gross C, Rossbacher L, Ellwart J, Riegger J, Multhoff G: The cell surface-localized heat shock protein 70 epitope TKD induces migration and cytolytic activity selectively in human NK cells.

24. J Immunol 2004, 172:972-980.

25. Bayer C, Liebhardt ME, Schmid TE, Trajkovic-Arsic M, Hube K, Specht HM, Schilling D, Gehrmann M, Stangl S, Siveke JT, Wilkens JJ, Multhoff G: Validation of heat shock protein 70 as a tumor-specific biomarker for monitoring the outcome of radiation therapy in tumor mouse models.

26. Int J Radiat Oncol Biol Phys 2014, 88:694-700.

27. Kleinjung T, Arndt O, Feldmann HJ, Bockmühl U, Gehrmann M, Zilch T, Pfister K, Schönberger J, Marienhagen J, Eilles C, Rossbacher L, Multhoff G: Heat shock protein 70 (Hsp70) membrane expression on head-and-neck cancer biopsy-a target for natural killer (NK) cells.

28. Int J Radiat Oncol Biol Phys 2003, 57:820-826.

29. Krause SW, Gastpar R, Andreesen R, Gross C, Ullrich H, Thonigs G, Pfister K, Multhoff G:Treatment of colon and lung cancer patients with ex vivo heat shock protein 70-peptide-activated, autologous natural killer cells: a clinical phase I trial.

30. Clin Cancer Res 2004, 10:3699-3707.

31. Dutta SK, Girotra M, Singla M, Dutta A, Otis Stephen F, Nair PP, Merchant NB: Serum HSP70: a novel biomarker for early detection of pancreatic cancer.

32. Pancreas 2012, 41:530-534.

33. Dakappagari N, Neely L, Tangri S, Lundgren K, Hipolito L, Estrellado A, Burrows F, Zhang H:An investigation into the potential use of serum Hsp70 as a novel tumor biomarker for Hsp90 inhibitors.

34. Biomarkers 2010, 15:31-38.

35. Baumann M, Liertz C, Baisch H, Wiegel T, Lorenzen J, Arps H: Impact of overall treatment time of fractionated irradiation on local control of human FaDu squamous cell carcinoma in nude mice.

36. Radiother Oncol 1994, 32:137-143.
    

37. Hurwitz MD, Kaur P, Nagaraja GM, Bausero MA, Manola J, Asea A: Radiation therapy induces circulating serum Hsp72 in patients with prostate cancer.

38. Radiother Oncol 2010, 95:350-358.

39. De Maio A: Heat shock proteins: facts, thoughts, and dreams.

40. Shock 1999, 11:1-12.

41. Gross C, Schmidt-Wolf IG, Nagaraj S, Gastpar R, Ellwart J, Kunz-Schughart LA, Multhoff G:Heat shock protein 70-reactivity is associated with increased cell surface density of CD94/CD56 on primary natural killer cells.

42. Cell Stress Chaperones 2003, 8:348-360.

43. Mitchell PS, Parkin RK, Kroh EM, Fritz BR, Wyman SK, Pogosova-Agadjanyan EL, Peterson A, Noteboom J, O'Briant KC, Allen A, Lin DW, Urban N, Drescher CW, Knudsen BS, Stirewalt DL, Gentleman R, Vessella RL, Nelson PS, Martin DB, Tewari M: Circulating microRNAs as stable blood-based markers for cancer detection.

44. Proc Natl Acad Sci USA 2008, 105:10513-10518.
    

45. Kocsis J, Madaras B, Toth EK, Fust G, Prohaszka Z: Serum level of soluble 70-kD heat shock protein is associated with high mortality in patients with colorectal cancer without distant metastasis.

46. Cell Stress Chaperones 2010, 15:143-151.
    

47. Zimmermann M, Nickl S, Lambers C, Hacker S, Mitterbauer A, Hoetzenecker K, Rozsas A, Ostoros G, Laszlo V, Hofbauer H, Renyi-Vamos F, Klepetko W, Dome B, Ankersmit HJ:Discrimination of clinical stages in non-small cell lung cancer patients by serum HSP27 and HSP70: a multi-institutional case–control study.

48. Clin Chim Acta 2012, 413:1115-1120.